WO2000018806A1 - Anticorps bispecifiques et trispecifiques reagissant de façon specifique avec des antigenes d'enveloppe pouvant etre induits, en tant que structures cibles operationnelles - Google Patents

Anticorps bispecifiques et trispecifiques reagissant de façon specifique avec des antigenes d'enveloppe pouvant etre induits, en tant que structures cibles operationnelles Download PDF

Info

Publication number
WO2000018806A1
WO2000018806A1 PCT/EP1999/007095 EP9907095W WO0018806A1 WO 2000018806 A1 WO2000018806 A1 WO 2000018806A1 EP 9907095 W EP9907095 W EP 9907095W WO 0018806 A1 WO0018806 A1 WO 0018806A1
Authority
WO
WIPO (PCT)
Prior art keywords
human
chl
igg3
target cell
hinge
Prior art date
Application number
PCT/EP1999/007095
Other languages
German (de)
English (en)
Inventor
Horst Lindhofer
Original Assignee
Horst Lindhofer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19859110A external-priority patent/DE19859110A1/de
Application filed by Horst Lindhofer filed Critical Horst Lindhofer
Publication of WO2000018806A1 publication Critical patent/WO2000018806A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Definitions

  • the present invention relates to new bispecific and trispecific antibodies, methods for producing these antibodies and their use in immunotherapy.
  • Immunotherapy using antibodies, especially bispecific or trispecific antibodies, has become increasingly important in recent years.
  • An essential problem when using such antibodies in immunotherapy is the specific recognition of the target cell by the antibodies, ie a differentiation as precisely as possible from the cells which are not to be attacked by the antibodies, ie the cells in the normal, physiological state.
  • bispecific and tri-specific antibodies which are used for immunotherapy. These bispecific and tri-specific antibodies are capable of binding positive cells (accessory cells) to a T cell, at least one antigen on a target cell and through their Fc part or through a third specificity to Fc receptor.
  • bispecific and trispecific antibodies when used in immunotherapy, only activate certain, clearly defined sub-areas of the immune system on a target cell and therefore the side effects that occur in a patient are also limited and therefore relatively easy to control
  • intact bispecific and trispecific antibodies produce much stronger side effects if the specificity of the binding arm that recognizes an antigen on a target cell is low.
  • intact bispecific and trispecific antibodies activate not only T cells, but also accessory cells, for example monocytes, macrophages and dendritic cells. These side effects could be reduced by allowing a highly specific recognition of the target cell by the antibody.
  • bispecific and trispecific antibodies which recognize a specific antigen on a target cell.
  • this object is achieved by an intact bispecific or trispecific antibody which has at least the following properties:
  • the antibody being selected such that it binds to a surface antigen as target antigen on the target cell which is inducible and does not occur in the uninduced state (normal state) on the target cell or in such a small number that the number is not sufficient to destroy the target cell.
  • small number means a number of target antigens on the target cell of more than 100 target antigens per target cell, preferably more than 300 and furthermore preferably more than 1000 target antigens per cell.
  • the inducible target antigens can also be present in an amount of up to 500,000 per target cell, with amounts of up to 400,000, up to 300,000, up to 200,000 or up to 100,000 being inducible per target cell. Another preferred amount range in which the target antigens can be is from 50,000 to 100,000 and from 5,000 to 50,000.
  • inducible surface antigens on target cells which are suitable for immunotherapy by intact bispe- specific and trispecific antibodies can be used are heat shock proteins and "MHC class I-related" MIC molecules.
  • Heat shock proteins are synthesized by the cell in response to cell stress.
  • cell stress includes, for example, degeneration of the cell, the action of radiation, chemical substances and of increased temperature on the cell, and infection of the cell by microorganisms.
  • heat shock proteins Four families of heat shock proteins are currently known, which are differentiated on the basis of their different molecular weights.
  • Hsp25, Hsp60, Hsp70 and Hsp90 the number representing the approximate molecular weight of the stress proteins in kilo-daltons.
  • the heat shock proteins are characterized by highly conserved amino acid sequences, the degree of conservation being over 35% amino acid identity, preferably 35-55%, further preferably 55-75% and most preferably between 75% to 85% amino acid identity .
  • Heat shock proteins are normally not expressed on healthy tissue. However, there are studies which show that heat shock proteins can be expressed, for example, on tumor cell lines and on tumor material from patients (Melcher et al., Nature Medicine, 4: 581, 1998). However, the expression of the heat shock proteins on the tumor cell lines is relatively weak and is therefore unsuitable for previously known immunotherapeutic approaches with monoclonal antibodies and incomplete (F (ab) 2) bispecific antibodies.
  • heat shock proteins examples include Hsp60 and Hsp70 / 72. The same applies to MIC molecules. These molecules can also be induced by cell stress, as defined in more detail above.
  • MIC molecules are MHC I-related molecules that are under the control of heat shock promoter elements (Groh et al., PNAS 93: 12445, 1996). Examples of MIC molecules are MIC A and MIC B.
  • MIC molecules are not expressed on normal tissue or only in such a small amount that they act as a target structure for detection by an antibody in order to destroy the target cell are not suitable, while they are expressed on, for example, epithelial tumors in such an amount that they can be used as target antigens in immunotherapy due to the bispecific and trispecific antibodies provided according to the invention.
  • the intact bispecific or trispecific antibodies provided according to the invention are selected such that they are directed against at least one target antigen on a target cell which is inducible and does not or does not occur essentially on the target cell in the non-induced state.
  • this number is approximately 100 target antigens / cell.
  • this does not mean that such target antigens cannot occur on other cells, ie non-target cells.
  • heat shock proteins occur on rapidly regenerating tissue, for example the mucous membrane cells of the gastrointestinal tract, even in a physiological state. However, these heat shock proteins are not included in the present invention, since they are not inducible, but already occur on normal tissue.
  • the rapidly regenerating tissue is thus not the primary target of the antibodies according to the invention, but can be "hit” by the antibodies if the antibody according to the invention not only recognizes the inducible target antigens on the target cell, but these antigens e.g. also occur on rapidly regenerating tissue. However, since this tissue divides quickly, the original state of this tissue can be restored relatively quickly after stopping the antibody therapy so that it can again perform its physiological task.
  • the invention is therefore not aimed at the bispecific and trispecific antibodies according to the invention antigens on e.g. recognize rapidly regenerating tissue, which may be constitutively expressed there, but the invention only includes those antibodies which are directed against target antigens which are inducible on the target cell and, after induction, for example also constitutively, are expressible.
  • inducible is understood to mean target antigens which here are tumor-specific operations and which do not occur in the physiological state on the cell or only occur in such a number that an immune response against them cannot be induced or a destruction of the target cells cannot or due to this small number takes place to an insignificant, therapeutically usable extent.
  • Inducible target antigens on a target cell are not only to be understood as those on a tumor cell, but also antigens that are induced when the target cell is infected, for example, by a microorganism.
  • microorganism is understood to mean any organism which influences the target cell in such a way that a target antigen induced by the microorganism is expressed on its surface to the extent described above.
  • Microorganisms are invented According to the invention, for example, bacteria, viruses, protozoa and fungi are understood. Bacteria include, for example, gram-positive and and gram-negative bacteria, mycoplasmas and rickettsia. The protozoa in particular include plasmodes.
  • the viruses include, for example, retroviruses, adenoviruses, herpes viruses, hepatitis viruses, togaviruses, poxviruses, etc. It is crucial that in cells which have been infected by one or more of these microorganisms, antigens are expressed on the cell surface which are caused by the microorganisms. Infection can be induced. These are antigens that are produced by the target cells in response to the microorganism infection and appear on the cell surface (host antigens), but not target antigens that are produced by the microorganisms themselves.
  • the infection of a target cell by a microorganism also leads to a cell stress situation for the cell, which in response induces the expression of certain proteins, for example heat shock proteins and MIC proteins.
  • the intact bispecific and trispecific antibodies provided according to the invention not only bring one type of immune cell, but T cells and accessory cells to the target cell, and for this reason they are particularly suitable for identifying inducible surface antigens as operational target structures. It could be shown that only a few target antigens in an amount of 100 to 5000 per cell on the target cell are sufficient to destroy them.
  • the in vitro experiments carried out for this purpose with stem cell preparations (PBSZ) are described in Example 1 below.
  • the class of intact bispecific and trispecific antibodies according to the invention is capable of destroying tumor cells or target cells even with a very low expression of the target antigens or of initiating an immune response after their recognition.
  • the antibodies according to the invention since they are directed against inducible antigens, can help to solve the problem of missing target cell-specific target antigens which are necessary for immunotherapy on tumor cells and on cells infected by microorganisms. Since such inducible antigens do not only occur on tumor cells, but are generally produced in stressful situations, diseases can also be tackled immunotherapeutically, which have been triggered by infection of, for example, viruses, unicellular organisms, bacteria or fungi. These are the MIC molecules and heat shock proteins already described in more detail above.
  • the intact bispecific or trispecific antibodies described above are used therapeutically to induce an immune response and / or to destroy the target cell.
  • the antibodies are administered in the form of a pharmaceutical preparation, which may contain conventional carriers and / or excipients, in order to enable stability and a favorable form of administration combined with high tolerability and effectiveness.
  • a pharmaceutical preparation which may contain conventional carriers and / or excipients, in order to enable stability and a favorable form of administration combined with high tolerability and effectiveness.
  • the antibodies provided according to the invention can be used in a relatively small amount, i.e. they are already effective in an amount of 5 ⁇ g to 10 mg per patient in order to bring about the immunity according to the invention, for example tumor immunity, or the destruction of the target cell which can be achieved according to the invention.
  • the application amount is preferably in the range from 10 ⁇ g to 100 ⁇ g per patient, but it can also, if necessary, be above that, ie in the range from 100 ⁇ g to 5 mg per patient.
  • MRD minimal residual disease
  • bispecific or trispecific antibodies administered that can be used according to the invention, the risk of serious side effects is significantly reduced.
  • Another advantage is that a humoral immune response is induced with complement-fixing antibodies (the IgGl and IgG3 isotypes in humans, which are able to destroy tumor cells).
  • Binding of the antibody to the Fc receptor positive cell activates the cell, thereby initiating or increasing the expression of cytokines and / or of co-stimulatory antigens.
  • the antibodies according to the invention transmit at least one second activation signal, which is required for a physiological activation of the T cell, through the co-stimulatory antigens on the accessory cell to the T cell, this activation being reflected in the upregulation of activation markers, the destruction the target cell and / or in a proliferation of the T cell.
  • tumor immunity preferably long-term tumor immunity
  • the immune response achievable according to the invention is thereby characterizes that in an organism the body's immune system is activated in such a way that there is permanent destruction and / or control of the tumor or the infectious disease. It is also advantageous when using the antibodies described here to reduce the side effects which commonly used antibodies, for example monoclonal antibodies, have.
  • the target structure for the antibodies according to the invention are inducible surface antigens according to the definition of the present invention, that is to say those which do not occur on the target cell or in a negligible amount, so that direct destruction of the target cell or an immune response, in particular a long-lasting immune response or immunity is not induced or at least is not induced to a therapeutically reasonable extent.
  • any type of tumor that can be treated under the definition given above can be treated.
  • Epithelial tumors, adenocarcinomas, colon carcinomas, breast carcinomas, ovarian carcinomas, lung carcinomas and neck, nose and / or ear tumors can be treated in particular.
  • Non-epithelial tumors such as leukemia and lymphoma can also be treated.
  • Virus-induced tumors for example liver tumors or cervical carcinomas, can also be treated.
  • target cells infected by microorganisms and the diseases induced thereby can also be treated. This includes, for example, infections from CMV and HIV.
  • target cell is understood to mean all cells that are degenerate in the form of a tumor cell or that have been infected by a microorganism and that, in response to the cell degeneration or the microorganism infection, express an antigen which is normal in the target cell, ie without degeneration or without infection, is not produced or to such a small extent that an immunotherapeutic pie is not inducible or an immunotherapeutic destruction of the target cell is not possible.
  • antibodies it is not possible to use any antibodies, but these must be intact, i.e. they must have a functional Fc part, and they are preferably heterologous in nature, i.e. the antibodies are then composed of heavy immunoglobulin chains of different subclasses (combinations, also fragments or individually exchanged amino acids) and / or origin (species).
  • bispecific and / or trispecific antibodies are used which are able to activate the Fc receptor-positive cell. This initiates or increases the expression of cytokines and / or co-stimulatory antigens.
  • the binding to the Fc receptor positive cells is preferably carried out, for example, via the Fc receptor from Fc receptor positive cells or also via other antigens on Fc receptor positive cells (antigen-presenting cells), such as e.g. the mannose receptor.
  • heterologous bispecific and / or trispecific antibodies which can be used according to the invention are known per se, but some are also described for the first time in the above application.
  • bispecific antibodies represent only one embodiment of the invention. It is also possible to use trispecific antibodies with the properties specified above. Furthermore, the invention is particularly illustrated using the example of induction of tumor immunity. However, this is also only one possible embodiment of the invention, which is very general for immunotherapeutic German purposes can be used. For example, it is also possible to use the antibodies provided according to the invention to achieve immunity to microorganisms which, among other things, induce the target antigens described here on the infected target cells.
  • the 1st signal is transmitted, for example, via the T cell receptor complex of the T cell and can therefore, viewed in isolation, lead to an unphysiological activation of the T cell.
  • the cell is anergized and can no longer react appropriately to stimuli mediated by T cells.
  • at least a second activation signal is also simultaneously transmitted to the T cell by the costimulatory antigens on the Fc receptor positive cell, which leads to a physiological activation of the T cell and subsequently to destruction the target cell and / or a proliferation of the T cell.
  • the upregulation of surface antigens such as CD2, CD25 and / or CD28 and / or the secretion of cytokines such as e.g. IL-2 or INF- ⁇ can be used.
  • T cells are activated and redirected against the target cells. Unspecific activations of T cells without redirection generally had little success in immunotherapy.
  • MHC 1 is upregulated on the target cell and the intracellular processing machinery (proteasome complex) is activated due to the release of cytokines (such as INF- ⁇ and TNF- ⁇ ) in the immediate vicinity of the target cell.
  • cytokines such as INF- ⁇ and TNF- ⁇
  • the cytokines are released due to bispecific antibody-mediated activation of T cells and accessory cells (see Fig. 1 and 3). This means that the intact bsAk not only destroys or phagocytizes target cells, but also indirectly their immunity, for example against the tumor, is increased.
  • the activation of the Fc receptor positive cell by the bsAk depends on the subclass or the subclass combination of the bsAk.
  • bsAk of the subclass combination mouse-IgG2a / - rat-IgG2b are able to bind positive cells to Fc receptor and to activate them at the same time, which leads to upregulation or new formation (expression) of costimulatory antigens, such as CD40, CD80 or CD86, on the cell surface of these cells.
  • costimulatory antigens such as CD40, CD80 or CD86
  • bsAk While the intact bsAk binds the T cell with a binding arm (e.g. to CD3 or CD2) and activates it at the same time, costimulatory signals can be transmitted from the Fc receptor positive cell bound to the Fc part of the bsAk to the T cell . That Only the combination of activation of the T cell via a binding arm of the bsAk and the simultaneous transmission of costimulatory signals from the Fc receptor positive cell to the T cell leads to an efficient T cell activation. Target cell-specific T cells that have been insufficiently activated on the target cell and are anergic can also be reactivated after an ex vivo long-term incubation treatment.
  • a binding arm e.g. to CD3 or CD2
  • Target cell-specific CD4 Another important aspect in the induction of target cell immunity is the possible phagocytosis, processing and presentation of target cell components by the accessory cells brought up and activated by the bsAk (monocytes / macrophages, dendritic cells and NK "natural killer” cells). This classic mechanism for the presentation of antigens enables both target cell-specific CD4 and CD8 posi tive cells are generated.
  • Target cell-specific CD4 cells also play an important role in inducing a humoral immune response in connection with TB cell cooperation.
  • Bispecific and trispecific antibodies can bind with one binding arm to the T cell receptor complex of the T cell, with the second binding arm to target cell-associated antigens on the target cell. They activate T cells that destroy the target cells through the release of cytokines or apoptosis-mediating mechanisms.
  • T-cells recognize tumor-specific antigens via their receptor as part of the activation with bispecific antibodies, thereby inducing permanent immunization.
  • the intact Fc part of the bispecific or trispecific antibody which binds to accessory cells such as e.g.
  • Monocytes / macrophages and dendritic cells are mediated and these cause themselves to become cytotoxic and / or at the same time pass on important costimulatory signals to the T cell (Fig. 1). In this way, a T cell response may obviously can also be induced against previously unknown, target-specific peptides.
  • the anergy of cytotoxic T could Cells are canceled.
  • a T cell tolerance existing in the patient against the target cell can be broken by means of intact heterologous bispecific and / or trispecific antibodies and thus permanent immunity, for example tumor immunity, can be induced.
  • the antibodies used according to the invention are preferably capable of reactivating target-specific T cells which are in anergy. Furthermore, they are able to induce tumor-reactive complement-binding antibodies and thus to induce a humoral immune response.
  • the binding is preferably via CD3, CD2, CD4, CD5, CD6, CD8, CD28 and / or CD44 to the T cell.
  • the Fc receptor positive cells have at least one Fc ⁇ receptor I, II or III.
  • Antibodies which can be used according to the invention are capable of binding to monocytes, macrophages, dendritic cells, "natural killer” cells (NK cells) and / or activated neutrophils as Fc ⁇ receptor 1 positive cells.
  • the antibodies which can be used according to the invention have the effect that the expression of CD40, CD80, CD86, ICAM-1 and / or LFA-3 as co-stimulatory antigens and / or the secretion of cytokines by the Fc receptor positive cell is initiated or increased.
  • the cytokines are preferably IL-1, IL-2, IL-4, IL-6, IL-8, IL-12 and / or TNF- ⁇ .
  • Binding to the T cell is preferably via the T cell receptor complex of the T cell.
  • bispecific antibodies which can be used according to the invention are preferred:
  • the trispecific antibodies which can be used according to the invention are preferred:
  • the trispecific antibodies which can be used according to the invention have at least one T cell binding arm, one target cell binding arm and one binding arm binding to Fc receptor.
  • This last-mentioned binding arm can be an anti-Fc receptor binding arm or a mannose receptor binding arm.
  • the bispecific antibody is preferably a heterologous intact rat / mouse bispecific antibody.
  • T cells are activated and redirected against the target cells.
  • Preferred heterologous intact bispecific antibodies are selected from one or more of the following isotype combinations:
  • Greenwood et. al. describe the possibility of exchanging individual immunoglobulin domains (eg CH2) using suitable cloning techniques.
  • This provides the technology to produce new antibody combinations, for example: human (VH-CHl, VL-CL) -human IgG4- (hinge) -human IgG4 (N-terminal region of CH2) -human IgG3 * (C-terminal Region of CH2:> amino acid position 251) -human IgG3 * (CH3).
  • human IgG4 to produce the bispecific antibody: human IgG4 / human- (VH-CHl, VL-CL) -human IgG4- (hinge) -human IgG4 (N-terminal region of CH2) -human IgG3 * (C-terminal region of CH2:> amino acid position 251) - human IgG3 * (CH3) is by simple cell fusion, as in Lindhofer et al. (J. Immunol. 155: 219, 1995).
  • the antibodies which can be used according to the invention are preferably monoclonal, chimeric, recombinant, synthetic, semisynthetic or chemically modified intact antibodies with, for example, Fv, Fab, scFv or F (ab) 2 fragments.
  • Antibodies or derivatives or fragments from humans are preferably used or those which are modified in such a way that they are suitable for use in humans (so-called "humanized antibodies") (see, for example, Shalaby et al., J. Exp. Med. 175 ( 1992), 217; Mocikat et al., Transplantation 57 (1994), 405).
  • onoclonal antibodies which originate preferably in mammals, e.g. Human, rat, mouse, rabbit or goat can be done using conventional methods such as those described in e.g. in Köhler and Milstein (Nature 256 (1975), 495), in Harlow and Lane (Antibodies, A Laboratory Manual (1988), Cold Spring Harbor) or in Galfre (Meth. Enzymol. 73 (1981), 3).
  • bispecific antibodies The production of antibodies with two different specificities, the so-called bispecific antibodies, is possible on the one hand by using recombinant DNA technology, but also by the so-called hybrid-hybridoma fusion technique (see, for example, Milstein et al., Nature 305 (1983), 537 ). Hybridoma cell lines that produce antibodies with one of the desired specificities are fused and recombinant cell lines are identified and isolated that produce antibodies with both specificities.
  • bispecific and trispecific antibodies That of the invention. underlying problem can be solved by both bispecific and trispecific antibodies, provided that they have the properties and characterized in claim 1 Have effects.
  • the production of antibodies with two and three specificities is described in more detail below. The provision of such bispecific and trispecific antibodies is part of the prior art, and full reference is made here to the literature describing such production techniques.
  • Antibodies with three specificities, so-called trispecific antibodies, by means of which the problem on which the invention is based can also be produced, can be produced, for example, in such a way that a third antigen binding site with a further specificity, e.g., to one of the heavy Ig chains of a bispecific antibody. in the form of a "single chain variable fragment" (scFv).
  • the scFv can, for example, use a
  • trispecific F (ab) 2 constructs can be prepared by replacing the CH2-CH3 regions of the heavy chain of a specificity of a bispecific antibody with an scFv with a third specificity, while the CH2-CH3 regions of the heavy chain of the other specificity, for example by inserting a stop codon (at the end of the "hinge” region) into the coding gene, for example by means of homologous recombination (see Fig. 2).
  • bispecific antibodies are used, for example.
  • Intact bispecific antibodies are made up of two antibody half-molecules (one H and one L immunoglobulin chain each) each represent specificity, composed, and, like normal antibodies, also have an Fc part with the known effector functions. They are preferably manufactured using Quadrom technology. This manufacturing process is described by way of example in DE-A-44 19 399. Reference is made in full to this document, also with regard to a definition of the bispecific antibodies, for complete disclosure. Of course, other production methods can also be used as long as they lead to the intact bispecific antibodies of the above definition that are necessary according to the invention.
  • bispecific antibodies instead of the bispecific antibodies, of course, trispecific antibodies can also be used as long as they meet the conditions.
  • Fig. 1 Representation of the antibodies of the invention and their
  • Fig. 2 Trispecific F (ab) 2 antibodies
  • Fig. 3 Trispecific scFv antibody
  • the antibodies according to the invention are used in order to achieve prophylaxis and therapy of tumor diseases and diseases caused by microorganisms by means of an ex vivo immunization method, in particular in order to achieve immunity to a tumor or to infection by microorganisms induce.
  • This ex vivo immunization method using the antibodies provided according to the invention comprises the following steps: a) isolation of autologous target cells; b) treating the target cells to prevent their survival after reinfusion; c) 30 minutes to 4 hours, preferably 30 minutes to 2 hours, before the inactivated target cells are reinfused, the intact bispecific and / or trispecific antibodies according to the invention are infused into the patient; d) reinfusion of the treated target cells in the patient.
  • target cells are understood to mean both tumor cells and cells which have been infected by microorganisms, for example by bacteria, viruses or fungi.
  • the preferred embodiment of the invention is illustrated below with the treatment of autologous tumor cells.
  • the invention is not restricted to this, but can also be applied to target cells which have been infected by microorganisms and on which host-specific antigens have been induced.
  • heterologous intact bispecific and / or trispecific antibodies are used.
  • the tumor cells were treated in a manner known per se, for example by radiation or heat treatment. After irradiation, the tumor cells are brought into contact with the intact heterologous bispecific and / or trispecific antibodies.
  • the antibodies are then from heavy immunoglobulin chains of different subclasses (combinations, also fragments) and / or origin (Species) composed.
  • This method and the use of the antibodies described here ensure that tumor immunity is built up after the antibody has been infused into the patient from whom the tumor cells were previously removed.
  • the treated tumor cells are preferably reinfused into a patient after the treatment of the primary tumor, preferably in patients in a minimal residual disease (MRD) situation.
  • MRD minimal residual disease
  • the method provided according to the invention can be used particularly successfully in patients with little remaining tumor cells, but in whom the risk of recurrence may be high.
  • the autologous tumor cells are first inactivated after they have been obtained. 30 minutes to 4 hours, preferably 30 minutes to 2 hours, before the treated target cells are reinfused, the intact bispecific and / or trispecific antibodies according to the invention are infused into the patient. The treated tumor cells are then prepared for reinfusion and infused.
  • the autologous tumor cells are also initially inactivated by, for example, radiation or an increase in temperature.
  • PBMC peripheral blood mononucleated cells
  • the bispecific and / or trispecific antibodies according to the invention are then added to this, and this mixture is then added over a longer period of time, for example 1 to 14 days long, preferably 3 to 10 days and further preferably 6 to 10 days.
  • PBMC peripheral blood mononucleated cells
  • the bispecific and / or trispecific antibodies according to the invention are then added to this, and this mixture is then added over a longer period of time, for example 1 to 14 days long, preferably 3 to 10 days and further preferably 6 to
  • T cells are redirected to the tumor cells by means of the intact bispecific and / or trispecific antibodies immobilized on the tumor cells; at the same time, Fc receptor positive cells bind to the Fc part of the bispecific and / or trispecific antibody after reinfusion.
  • the Fc receptor positive cells are activated by binding to the Fc parts of intact bispecific antibodies immobilized (on the T cell or tumor cell).
  • the tumor cells treated with the antibodies can not only be applied to the patient once, but optionally also administered several times.
  • MHC 1 is upregulated on the tumor cell and the intracellular processing machinery (proteasome complex) is activated due to the release of cytokines (such as INF- ⁇ and TNF-) in the immediate vicinity of the tumor cell.
  • cytokines such as INF- ⁇ and TNF-
  • the cytokines are released due to bispecific antibody-mediated activation of T cells and accessory cells (see Fig. 1 and 3). This means that the intact bsAk not only destroys or phagocytizes tumor cells, it also who also indirectly increases their tumor immunity.
  • the activation of the Fc receptor positive cell by the bsAk depends on the subclass or the subclass combination of the bsAk.
  • bsAk of the subclass combination mouse-IgG2a / - rat-IgG2b are able to bind positive cells to Fc receptor and to activate them at the same time, which leads to upregulation or new formation (expression) of costimulatory antigens, such as CD40, CD80 or CD86, on the cell surface of these cells.
  • costimulatory antigens such as CD40, CD80 or CD86
  • bsAk While the intact bsAk binds the T cell with a binding arm (eg to CD3 or CD2) and simultaneously activates it, costimulatory signals can be transmitted from the Fc receptor positive cell bound to the Fc part of the bsAk to the T cell . That Only the combination of activation of the T cell via a binding arm of the bsAk and the simultaneous transmission of costimulatory signals from the Fc receptor positive cell to the T cell leads to an efficient T cell activation. Tumor-specific T cells that have been insufficiently activated on the tumor cell and are anergic can also be reactivated after the ex vivo pretreatment according to the invention.
  • a binding arm eg to CD3 or CD2
  • Tumor-specific CD4 cells play also play an important role in the induction of a humoral immune response in connection with TB cell cooperation.
  • the mononuclear cells from the peripheral blood are mixed with the inactivated, autologous tumor cells and incubated together with the antibodies for a period of 1-14 days, more preferably 3 to 10 days, further preferably 6 to 10 days.
  • GMP Good Manufacturing Production
  • the above-mentioned incubation conditions are only to be understood as examples. Depending on the tumor cells and the antibodies used, other time periods, temperature conditions etc., generally other incubation conditions, can also be selected. The person skilled in the art can determine these conditions by simple experiments.
  • the tumor cells are preferably used in an amount of 10 7 to 10 9 cells, further preferably in an amount of approx. 10 8 cells.
  • the mononuclear cells from the peripheral blood are added in an amount of approximately 10 8 to 10 10 cells.
  • incubation conditions which can be determined by laboratory tests (for example changes in the number of cells and duration of the incubation).
  • the autologous tumor cells used are irradiated, for example, to prevent further survival of the tumor cells after reinfusion.
  • ⁇ -rays are used, which are used, for example, in a dose strength of 20 to 200 Gy.
  • the antibodies used according to the invention are preferably capable of reactivating tumor-specific T cells which are in anergy. Furthermore, they are able to induce tumor-reactive complement-binding antibodies and thus to induce a humoral immune response.
  • IV intravenously.
  • the advantage of the method disclosed here lies in the "self-sufficiency" with those for the high-regulation tion of, for example, MHC 1 on the tumor cell required cytokines (such as INF- ⁇ or TNF- ⁇ ) by the simultaneous activation of T cells and accessory cells (monocytes / macrophages, Fig.) on the tumor cell.
  • cytokines such as INF- ⁇ or TNF- ⁇
  • the antibodies according to the invention are used in order to reduce the number of contaminating target cells in stem cell transplants ex vivo.
  • This method is characterized in that the intact bispecific and trispecific antibodies provided according to the invention are brought into contact with stem cell transplants which may contain contaminating target cells for a sufficiently long period of time in order to at least reduce the number of contaminating target cells in the stem cell transplant.
  • stem cell transplants from patients with breast carcinoma or ovarian carcinoma or from patients with leukemia, lymphoma, testicular carcinoma or other chemotherapy sensitive carcinomas are treated here.
  • stem cell transplants from patients who are infected by microorganisms, for example by viruses can also be treated.
  • stem cell transplants infected with viruses are those infected with CMV or HIV.
  • the bispecific and trispecific antibodies which can be used according to the invention have already been described above.
  • the stem cell transplant is incubated with the bispecific antibodies for a period of 4 to 72 hours, preferably for a period of 24 to 48 hours, for example a temperature in the range from 20 to 25 ° C., preferably room temperature, is selected
  • stem cell transplants have a density of 30,000 to 75,000 cells per ⁇ l.
  • the stem cell transplants are reinfused into the patient, possibly after further purification.
  • the full content of the reader is referred to DE 196 49 223.8, the disclosure content of which is fully integrated in the above application.
  • contaminating tumor cells in stem cell preparations are eliminated in vitro by means of bispecific or trispecific antibodies.
  • These antibodies have the features specified in claim 1, in particular these antibodies are selected so that they bind to a surface antigen as target antigen on the target cell which is inducible and does not occur in the non-induced state (normal state) or in such a small number that the number is not sufficient for destruction of the target cell or induction of an immune response by the antibody.
  • the bispecific antibodies and the stem cells are brought into contact with the contaminating target cells under conditions which both bind the bispecific or trispecific antibodies to the target cells and the T cells as well as maintaining the viability of the stem cells. Adherence to these parameters is necessary for the maintenance and vitality of both stem cells and lymphocytes.
  • the stem cell transplant (leukapheresis product) is incubated for approximately 4-72 hours, preferably 24-48 hours, with bispecific antibodies at room temperature and a cell density of 30,000-75,000 cells / ⁇ l, preferably 30,000-50,000 cells / ⁇ l, with gentle swirling. With a total cell count of approx.
  • a bsAk amount of 5 - 50, 50 - 100, 100 - 500 ⁇ g is sufficient for tumor cell destruction.
  • Another important point of the method according to the invention is the use of so-called intact bispecific or trispecific antibodies. These are not only able (due to the specificities used here) to deliver T cells to the tumor cells, but they are also suitable due to the effector functions of the Fc part, by means of complement mediated lysis or by binding of Fc receptor positive cells , such as macrophages, monocytes or activated neutrophil granulocytes, to destroy tumor cells. Intact BSA can thus activate several tumor cell-destroying mechanisms at the same time.
  • the antibodies provided according to the invention are capable of recognizing and binding inducible surface antigens to target cells and initiating an immune response or destroying the target cell, even if the target structures are present in an extremely small amount on the target cell , for example in an amount of 100 to 10,000 per cell.
  • the target structures can also be present in greater numbers, for example up to 500,000 (further preferred areas are shown above).
  • the antibodies according to the invention surprisingly also work when the target structures are present on the target cell in a number of approximately 100, surprisingly, Even with this small number of target structures, only the smallest amounts of the antibody are necessary to carry out an effective therapeutic treatment, ie amounts of approximately 5 ⁇ g can be sufficient for the treatment.
  • the combination of antibody and tumor cells is preferably administered several times to the patient, the number of infusions depending on the tumor to be treated and on the patient and possibly other factors.
  • the immunogenicity of the tumor cells is increased by subjecting them to a heat pretreatment before administration.
  • a preferred heat pretreatment is carried out over a period of, for example, 1-6 hours, preferably approximately 3 hours, over a temperature range of 41-42 ° C., preferably at a temperature of approximately 41.8 ° C. Both the treatment duration and the treatment temperature depend on the type of tumor to be treated. The temperature to be used and the heat pretreatment period can be determined by the person skilled in the art by experiments.
  • the experiments were structured in such a way that aliquots were taken from PBSZ preparations treated in this way and contaminated with a defined amount of tumor cells. It could be shown that the tumor cells are destroyed even at this low concentration of intact bsAk, in which only a part of the target antigens are occupied.
  • Number of holes with tumor growth of 6 or 12 plated holes, after 14 days of cultivation.
  • An intact bsAk has a molecular weight of 150 KDa. Ie 1 mole is 150 kg and by definition corresponds to 6xl0 23 molecules. So 5 ⁇ g corresponds to approx. 2xl0 13 molecules.
  • each bsAk has an anti-CD3 binding arm, it can be concluded that theoretically, if you compare the two amounts of molecules calculated above, in this specific example no more than approx. 3000 CD3 molecules can be occupied by the bsAk.

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Selon l'invention, on obtient un anticorps intact bispécifique ou trispécifique qui présente au moins les propriétés suivantes: a) liaison à une cellule T; b) liaison à au moins un antigène sur une cellule cible; c) liaison par son fragment Fc (dans le cas d'anticorps bispécifiques) ou par une troisième spécificité (dans le cas d'anticorps trispécifiques) . L'antigène cible peut être induit et, à l'état non induit (état normal), il ne se trouve pas sur la cellule cible ou bien il s'y trouve en un nombre trop petit pour permettre une destruction de la cellule cible.
PCT/EP1999/007095 1998-09-25 1999-09-22 Anticorps bispecifiques et trispecifiques reagissant de façon specifique avec des antigenes d'enveloppe pouvant etre induits, en tant que structures cibles operationnelles WO2000018806A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19844157 1998-09-25
DE19844157.6 1998-09-25
DE19859110A DE19859110A1 (de) 1998-09-25 1998-12-21 Bispezifische und trispezifische Antikörper, die spezifisch mit induzierbaren Oberflächenantigenen als operationelle Zielstrukturen reagieren
DE19859110.1 1998-12-21

Publications (1)

Publication Number Publication Date
WO2000018806A1 true WO2000018806A1 (fr) 2000-04-06

Family

ID=26049097

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/007095 WO2000018806A1 (fr) 1998-09-25 1999-09-22 Anticorps bispecifiques et trispecifiques reagissant de façon specifique avec des antigenes d'enveloppe pouvant etre induits, en tant que structures cibles operationnelles

Country Status (1)

Country Link
WO (1) WO2000018806A1 (fr)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10043437A1 (de) * 2000-09-04 2002-03-28 Horst Lindhofer Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
WO2002083738A1 (fr) * 2001-04-11 2002-10-24 Institute Of Genetics, Cas Anticorps trispecifique monocatenaire cyclique
WO2003057732A2 (fr) * 2002-01-14 2003-07-17 William Herman Ligands cibles
EP2033657A1 (fr) * 2007-09-04 2009-03-11 Trion Pharma Gmbh Application d'anticorps intra-opératoire trifonctionnelle pour la prophylaxie de la dissémination des cellules cancérigènes intrapéritonéales
CN103429737A (zh) * 2010-11-30 2013-12-04 中外制药株式会社 细胞毒诱导治疗剂
US9017676B2 (en) 2006-02-15 2015-04-28 Horst Lindhofer Destruction of tumor cells by trifunctional bispecific antibodies with low to medium expression levels of tumor-associated target antigens
WO2015184203A1 (fr) 2014-05-29 2015-12-03 Macrogenics, Inc. Molécules de liaison trispécifiques et leurs procédés d'utilisation
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
US9975966B2 (en) 2014-09-26 2018-05-22 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing theraputic agent
CN108264561A (zh) * 2016-12-30 2018-07-10 上海近岸生物科技有限公司 一种结合cd19、cd3和t细胞负共刺激分子的三功能分子及其应用
US11072666B2 (en) 2016-03-14 2021-07-27 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
US11174315B2 (en) 2015-10-08 2021-11-16 Macrogenics, Inc. Combination therapy for the treatment of cancer
US11485790B2 (en) 2014-04-07 2022-11-01 Chugai Seiyaku Kabushiki Kaisha Immunoactivating antigen-binding molecule
US11505605B2 (en) 2014-05-13 2022-11-22 Chugai Seiyaku Kabushiki Kaisha T cell-redirected antigen-binding molecule for cells having immunosuppression function
US11649293B2 (en) 2015-11-18 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for enhancing humoral immune response
US11649262B2 (en) 2015-12-28 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
US11660340B2 (en) 2015-11-18 2023-05-30 Chugai Seiyaku Kabushiki Kaisha Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
EP4268831A2 (fr) 2018-09-12 2023-11-01 Fred Hutchinson Cancer Center Réduction de l'expression de cd33 pour protéger sélectivement des cellules thérapeutiques
US11851476B2 (en) 2011-10-31 2023-12-26 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993008829A1 (fr) * 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions induisant la destruction de cellules infectees par l'hiv
EP0637593A1 (fr) * 1993-08-02 1995-02-08 MERCK PATENT GmbH Molécules de déclenchement bispécifiques pour reconnaître l'antigène lymphocytaire CD2 et des antigènes tumorales
DE4431300C1 (de) * 1994-09-02 1996-02-08 Marcel Dr Med Falana Verfahren zur histologischen Diagnostizierung benigner und maligner Hautläsionen
EP0826696A1 (fr) * 1996-09-03 1998-03-04 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Utilisation des anticorps bi- et trispécifiques pour induire une immunité antitumorale
DE19649223A1 (de) * 1996-09-03 1998-03-05 Gsf Forschungszentrum Umwelt Zerstörung von kontaminierenden Tumorzellen in Stammzelltransplantaten mit bispezifischen Antikörpern

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993008829A1 (fr) * 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions induisant la destruction de cellules infectees par l'hiv
EP0637593A1 (fr) * 1993-08-02 1995-02-08 MERCK PATENT GmbH Molécules de déclenchement bispécifiques pour reconnaître l'antigène lymphocytaire CD2 et des antigènes tumorales
DE4431300C1 (de) * 1994-09-02 1996-02-08 Marcel Dr Med Falana Verfahren zur histologischen Diagnostizierung benigner und maligner Hautläsionen
EP0826696A1 (fr) * 1996-09-03 1998-03-04 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Utilisation des anticorps bi- et trispécifiques pour induire une immunité antitumorale
DE19649223A1 (de) * 1996-09-03 1998-03-05 Gsf Forschungszentrum Umwelt Zerstörung von kontaminierenden Tumorzellen in Stammzelltransplantaten mit bispezifischen Antikörpern

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CAMPBELL F A ET AL: "The role of tumor rejection antigens in host antitumor defense mechanisms.", CANCER, (1995 JUN 1) 75 (11) 2649-55. REF: 88, XP000877103 *
ZEIDLER R ET AL: "Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing.", JOURNAL OF IMMUNOLOGY, (1999 AUG 1) 163 (3) 1246-52., XP000877131 *

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8277806B2 (en) 2000-09-04 2012-10-02 Trion Pharma Gmbh Use of trifunctional bispecific and trispecific antibodies for the treatment of malignant ascites
DE10043437A1 (de) * 2000-09-04 2002-03-28 Horst Lindhofer Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
WO2002083738A1 (fr) * 2001-04-11 2002-10-24 Institute Of Genetics, Cas Anticorps trispecifique monocatenaire cyclique
CN1294148C (zh) * 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 环状单链三特异抗体
WO2003057732A2 (fr) * 2002-01-14 2003-07-17 William Herman Ligands cibles
WO2003057732A3 (fr) * 2002-01-14 2003-10-02 William Herman Ligands cibles
US9017676B2 (en) 2006-02-15 2015-04-28 Horst Lindhofer Destruction of tumor cells by trifunctional bispecific antibodies with low to medium expression levels of tumor-associated target antigens
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
US10934344B2 (en) 2006-03-31 2021-03-02 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
US8663638B2 (en) 2007-09-04 2014-03-04 Trion Pharma Gmbh Intraoperative trifunctional antibody application for prophylaxis of intraperitoneal tumor cell dissemination
WO2009030734A1 (fr) * 2007-09-04 2009-03-12 Trion Pharma Gmbh Application peropératoire d'anticorps trifonctionnels pour prévenir la dissémination intrapéritonéale de cellules tumorales
EP2033657A1 (fr) * 2007-09-04 2009-03-11 Trion Pharma Gmbh Application d'anticorps intra-opératoire trifonctionnelle pour la prophylaxie de la dissémination des cellules cancérigènes intrapéritonéales
CN103429737A (zh) * 2010-11-30 2013-12-04 中外制药株式会社 细胞毒诱导治疗剂
CN103429737B (zh) * 2010-11-30 2020-07-14 中外制药株式会社 细胞毒诱导治疗剂
US11066483B2 (en) 2010-11-30 2021-07-20 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
US11851476B2 (en) 2011-10-31 2023-12-26 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
US11485790B2 (en) 2014-04-07 2022-11-01 Chugai Seiyaku Kabushiki Kaisha Immunoactivating antigen-binding molecule
US11505605B2 (en) 2014-05-13 2022-11-22 Chugai Seiyaku Kabushiki Kaisha T cell-redirected antigen-binding molecule for cells having immunosuppression function
US11697684B2 (en) 2014-05-29 2023-07-11 Macrogenics, Inc. Tri-specific binding molecules that specifically bind to multiple cancer antigens
US10647768B2 (en) 2014-05-29 2020-05-12 Macrogenics, Inc. Multi-chain polypeptide-containing tri-specific binding molecules
WO2015184203A1 (fr) 2014-05-29 2015-12-03 Macrogenics, Inc. Molécules de liaison trispécifiques et leurs procédés d'utilisation
US11820818B2 (en) 2014-05-29 2023-11-21 Macrogenics, Inc. Multi-chain polypeptide-containing tri-specific binding molecules
EP3954703A2 (fr) 2014-05-29 2022-02-16 MacroGenics, Inc. Molécules de liaison trispécifiques et leurs procédés d'utilisation
US10633440B2 (en) 2014-05-29 2020-04-28 Macrogenics, Inc. Multi-chain polypeptide-containing tri-specific binding molecules that specifically bind to multiple cancer antigens
US11001643B2 (en) 2014-09-26 2021-05-11 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
US9975966B2 (en) 2014-09-26 2018-05-22 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing theraputic agent
US11174315B2 (en) 2015-10-08 2021-11-16 Macrogenics, Inc. Combination therapy for the treatment of cancer
US11649293B2 (en) 2015-11-18 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for enhancing humoral immune response
US11660340B2 (en) 2015-11-18 2023-05-30 Chugai Seiyaku Kabushiki Kaisha Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
US11649262B2 (en) 2015-12-28 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
US11072666B2 (en) 2016-03-14 2021-07-27 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
CN108264561A (zh) * 2016-12-30 2018-07-10 上海近岸生物科技有限公司 一种结合cd19、cd3和t细胞负共刺激分子的三功能分子及其应用
EP4268831A2 (fr) 2018-09-12 2023-11-01 Fred Hutchinson Cancer Center Réduction de l'expression de cd33 pour protéger sélectivement des cellules thérapeutiques

Similar Documents

Publication Publication Date Title
EP0885614B1 (fr) Procédé d'immunisation ex vivo utilisant des anticorps hétérologues intactes bispécifiques ou trispécifiques
EP1115427B1 (fr) Utilisation de cellules tumorales avec un decalage temporel en combinaison avec des anticorps intacts pour l'immunisation
WO2000018806A1 (fr) Anticorps bispecifiques et trispecifiques reagissant de façon specifique avec des antigenes d'enveloppe pouvant etre induits, en tant que structures cibles operationnelles
EP1315520B1 (fr) Utilisation d'anticorps trifonctionnels bispecifiques et trispecifiques dans le traitement d'ascites malignes
EP0826696B1 (fr) Utilisation des anticorps bi- et trispécifiques pour induire une immunité antitumorale
EP1444268B1 (fr) Molecule d'anticorps anti-cd28 bispecifique
DE69909459T2 (de) Cd19xcd3 spezifische polypeptide und deren verwendung
DE69533331T2 (de) Liganden zur induktion der antigen-spezifischen apoptose in t-zellen
DE60313859T2 (de) Induktion der anti-tumor-ctl-immunität durch in-vivo-aktivierung von 4-1bb und/oder cd40
DE69927262T2 (de) Cd40 bindende antikörper und ctl peptide zur behandlung von tumoren
DE19722888A1 (de) Human-CD28 spezifische monoklonale Antikörper zur antigenunspezifischen Aktivierung von T-Lymphozyten
EP1303540B1 (fr) Reactif multispecifique destine a la stimulation selective de recepteurs de surface cellulaire
EP1600164A2 (fr) Utilisation d'une substance liant le CD28 dans la production d'une composition pharmaceutique à effet dose-dépendant
WO1999049881A2 (fr) Utilisation de proteines hsp70
DE10050935A1 (de) Verwendung CD28 spezifischer monoklonaler Antikörper zur Stimulation von Blutzellen, welche kein CD28 tragen
EP1171587B1 (fr) Peptide derive de l'antigene muc-1 destine a declencher une reaction immunitaire contre des cellules tumorales
DE19859110A1 (de) Bispezifische und trispezifische Antikörper, die spezifisch mit induzierbaren Oberflächenantigenen als operationelle Zielstrukturen reagieren
EP1308167A1 (fr) Vésicles présentatrices d'antigène
DE19710497C2 (de) Verwendung Bi- und trispezifische Antikörper zur Induktion einer Tumorimmunität
EP0825256B1 (fr) Cellule hybride et son utilisation pour préparer un médicament pour induire une réponse immune contre une tumeur
EP0978559B1 (fr) Induction d'immunité tumorale par redirection de cellules tumorales contre des cellules présentatrices de l'antigène
DE19516673A1 (de) Vakzine gegen Tumorerkrankungen
DE69731950T2 (de) Tumorvakzinierung mittels Verwendung autologer oder HLA-verwandter Antigen präsentierender Zellen (APC), die mit einem Tumorantigen sowie einem eine Immunantwort hervorrufenden Fremdantigen transduziert sind
WO2004006950A2 (fr) Utilisation de cd152 pour le traitement de maladies auto-immunes et d'inflammations
DE19813760A1 (de) Neue Verwendung von Hsp70-Protein

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase